Banner MD Anderson Cancer Center, Division of Diagnostic Imaging, Gilbert, Arizona (V.A.L.).
Banner MD Anderson Cancer Center, Division of Cancer Medicine, Gilbert, Arizona (R.C.L., J.M.S., L.A.M.).
Acad Radiol. 2022 Jan;29 Suppl 1:S239-S245. doi: 10.1016/j.acra.2020.12.005. Epub 2020 Dec 16.
Pathogenic mutations in some genes elevate women's breast cancer risk, necessitating risk-reduction strategies. Unfortunately, women are underscreened for cancer risk, and when identified as potentially high risk, women seldom pursue genetic counseling or testing. To improve cancer risk management, this project determined the feasibility of radiology-operated, proactive, same-day risk assessment and genetic testing programs to diagnose high-risk women undergoing breast imaging.
The Comprehensive Assessment, Risk & Education Program launched on June 5, 2019. Data was tracked through July 22, 2020. Women undergoing breast imaging completed questionnaires that calculated Tyrer-Cuzick risk and assessed genetic testing eligibility using National Comprehensive Cancer Network criteria. To encourage eligible women's genetic testing adherence, pretest counseling and saliva sample collection occurred that same day in the imaging center. Samples were tested by a 34-multigene panel. Genetic counselors called women with positive results. Women with negative results or variants of uncertain significance were mailed notifications. Summary statistics were calculated.
A total of 3345 women completed questionnaires. 1080 (32.3%) met genetic testing criteria. 468/1080 (43.3%) submitted genetic samples, and 416/1080 (38.5%) completed testing. Of 416 completed tests, 269 (64.7%) tested negative, 109 (26.2%) had variants of uncertain significance, and 38 (9.1%) diagnosed pathogenic mutations. 13/38 (34.2%) women with pathogenic mutations implemented risk-reduction strategies at our institution.
Breast imaging centers can operate same-day cancer risk assessment and genetic testing programs, identifying high-risk women that conventional risk assessment methods may not have diagnosed. These proactive programs add value to radiology departments' cancer care beyond traditional imaging services.
某些基因的致病突变会增加女性患乳腺癌的风险,因此需要采取降低风险的策略。不幸的是,女性接受癌症风险筛查的比例较低,而且当被确定为潜在高风险时,很少有女性会选择进行遗传咨询或检测。为了改善癌症风险管理,本项目旨在确定放射科主导的、主动的、当日完成的风险评估和基因检测计划在诊断接受乳房影像学检查的高风险女性中的可行性。
全面评估、风险和教育计划于 2019 年 6 月 5 日启动。数据跟踪至 2020 年 7 月 22 日。接受乳房影像学检查的女性完成了问卷,该问卷根据 Tyrer-Cuzick 风险评分和国家综合癌症网络标准评估了基因检测的资格。为了鼓励符合条件的女性进行基因检测,当日在影像中心进行了检测前咨询和唾液样本采集。样本通过 34 基因多态性检测面板进行检测。遗传咨询师会给检测结果阳性的女性打电话。对于检测结果阴性或意义不确定的变异体,会将通知邮寄给女性。计算了描述性统计数据。
共有 3345 名女性完成了问卷。1080 名(32.3%)符合基因检测标准。其中 468/1080(43.3%)提交了基因样本,416/1080(38.5%)完成了检测。在完成的 416 项检测中,269 项(64.7%)检测结果为阴性,109 项(26.2%)为意义不确定的变异体,38 项(9.1%)诊断出致病性突变。在 38 名致病性突变女性中,有 13 名(34.2%)在本机构实施了降低风险的策略。
乳房影像中心可以开展当日癌症风险评估和基因检测计划,从而识别传统风险评估方法可能未诊断出的高风险女性。与传统的影像服务相比,这些主动的计划为放射科部门的癌症护理增加了价值。